Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. Schneider LS, Geffen Y, Rabinowitz J, Thomas RG, et al. Neurology 2019;93:e1474-e1484.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Schneider LS, Geffen Y, Rabinowitz J, Thomas RG, et al. Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. Neurology 2019;93:e1474-e1484.
PMID: 31492718